Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Proof of Principle Program - Phase I

University of Toronto

$150,000.00

Bioreactor-based large scale production of a Tim-3 pathway inhibitor as a novel immunotherapy against HIV-1 and other chronic viral infections

FY 2008-09

Summary
One of the greatest mysteries of Human Immunodeficiency Virus Type 1 (HIV-1) infection has been to understand why the normal immune system is unable to eradicate or control this virus infection as opposed to other virus infections. Our laboratory specializes in understanding how one arm of the immune system, called the T cells, fights viruses, including HIV-1 virus, the virus that causes AIDS (acquired immunodeficiency syndrome). It has been found that these T cells that are supposed to fight HIV-1 do a bad job, and have been called dys-functional, or ¿exhausted¿. Recently a clue to why these T cells are exhausted was demonstrated by numerous publications that have identified a new molecule on the surface of these exhausted cells called PD-1. We have now identified, another new molecule on the surface of these exhausted T cells called Tim-3 (T cell immunoglobulin mucin molecule type 3). We have found that Tim-3 identifies the most exhausted of these T cells. We also show that by blocking the action of this Tim-3 molecule on the T cell, we can rescue the function of these cells to fight HIV better. The current proposal will be used to develop a new immune therapy using state of the art technology and will be tested in the test tube and animals prior to use in humans.
Program
Proof of Principle Program - Phase I
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
174453
Name
Ostrowski Mario A
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Infection and Immunity
Theme2
Biomedical
Prcname2
Proof of Principle
Projecttitle
Bioreactor-based large scale production of a Tim-3 pathway inhibitor as a novel immunotherapy against HIV-1 and other chronic viral infections
Programtype2
Operating Grants
Orgnameinp2
University of Toronto
Cihramount2
$150,000
Cihrequipment2
$0
Programname2
Proof of Principle Program - Phase I
Keyworddelim
Aids; Bio-Reactor; Glycoprotein; Hiv; Immune Therapy; T Cell
Abstract
One of the greatest mysteries of Human Immunodeficiency Virus Type 1 (HIV-1) infection has been to understand why the normal immune system is unable to eradicate or control this virus infection as opposed to other virus infections. Our laboratory specializes in understanding how one arm of the immune system, called the T cells, fights viruses, including HIV-1 virus, the virus that causes AIDS (acquired immunodeficiency syndrome). It has been found that these T cells that are supposed to fight HIV-1 do a bad job, and have been called dys-functional, or ¿exhausted¿. Recently a clue to why these T cells are exhausted was demonstrated by numerous publications that have identified a new molecule on the surface of these exhausted cells called PD-1. We have now identified, another new molecule on the surface of these exhausted T cells called Tim-3 (T cell immunoglobulin mucin molecule type 3). We have found that Tim-3 identifies the most exhausted of these T cells. We also show that by blocking the action of this Tim-3 molecule on the T cell, we can rescue the function of these cells to fight HIV better. The current proposal will be used to develop a new immune therapy using state of the art technology and will be tested in the test tube and animals prior to use in humans.
Competitiondate
200810
Approvedterm2
1 yr 0 mth
Pinamesdelim
Ostrowski, Mario A
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $150,000~ $0~
University of Toronto - $150,000 Grant (2008-09) | Canada Spends